Passage Bio Inc.

05/26/2026 | Press release | Distributed by Public on 05/26/2026 05:15

Proxy Results (Form 8-K)

Item 5.07. Submission of Matters to a Vote of Security Holders.

On May 19, 2026, Passage Bio, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") and the following proposals were adopted:

1. Election of two Class III directors, identified in the table below, each to serve a three-year term, which will expire at the 2029 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until their earlier resignation or removal:
Nominees Shares
For 		Shares
Withheld 		Broker
Non-Votes
Athena Countouriotis, M.D. 971,120 519,093 637,397
Sandip Kapadia 972,608 517,605 637,397
2. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026:
Shares
For 		Shares
Against 		Shares
Abstaining 		Broker
Non-Votes
2,083,031 41,539 3,040 -
3. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement for the Annual Meeting:
Shares
For 		Shares
Against 		Shares
Abstaining 		Broker
Non-Votes
1,452,505 36,352 1,356 637,397
4. Approval, on a non-binding advisory basis, of the frequency of holding future advisory votes on named executive officer compensation:
Shares for
One Year 		Shares for
Two Years 		Shares for
Three Years 		Shares
Abstaining 		Broker
Non-Votes
1,450,605 5,046 28,143 6,419 637,397

The Company's stockholders advised that they were in favor of every year as the frequency of holding future advisory votes on the compensation of the Company's named executive officers. Based on these results and consistent with the Company's recommendation, the Company's board of directors has determined that the Company will conduct future advisory votes regarding the compensation of its named executive officers every year. This policy will remain in effect until the next required stockholder vote on the frequency of advisory votes on the compensation of the Company's named executive officers.

Passage Bio Inc. published this content on May 26, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on May 26, 2026 at 11:15 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]